Targeted collaborations Opportunity to pursue strategic partnerships with larger genomics players and instrument manufacturers that already have established distribution networks and customer bases in single-cell research, enabling co-developed solutions or integrated workflows around HIVE and BeeNetPLUS.

Expand through integration Leverage recent integrations with Factorial Diagnostics and existing workflows to position Honeycomb as a scalable, end-to-end single-cell processing solution that complements standard lab equipment, appealing to both research labs and contract service providers seeking high-throughput capabilities.

Multiplex product upsell Cross-sell or upsell related HIVE offerings (scRNAseq tools, BeeNetPLUS analysis) to current customers of PerkinElmer, Revvity, or other partners involved in single-cell workflows who could benefit from a seamless end-to-end platform.

Leverage niche scale Target small to mid-sized biotechs and clinical research groups pursuing precision medicine who require scalable single-cell capture and analysis without large capital equipment investments, highlighting the HIVE single-use model as a cost-effective entry point.

Revenue growth focus Position Honeycomb’s high-value capabilities to potential investors and customers by emphasizing a rapid growth trajectory in revenue range and the ability to process up to one million cells per day when integrated with external library prep chemistry, signaling high throughput potential.